Onkológia 4/2023
Current treatment options for metastatic hormone-sensitive prostate cancer
The critical role of androgens in stimulating prostate cancer growth led to the development of androgen deprivation therapy, which is still mainstain in the treatment for males with metastatic prostate cancer. Contemporary research has led to the multiple combined modality approaches that are associated with better outcomes than can be achieved with ADT alone. Current guidelines reccomend dublet or triplet terapies. This topic discuss initial systemic therapy options for management of metastatic CSPC.
Keywords: castrate sensitive, prostate cancer, androgen deprivation therapy
